Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Inflammation therapy
US9763894B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9763894-B2 |
| Application number | US-95045607-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 5, 2007 |
| Priority date | Dec 5, 2006 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB 2 receptor but having substantially no efficacy at the CB 1 receptor at that amount.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cerebral ischemia/reperfusion injury or spinal cord injury in a patient in need thereof or preventing spinal cord injury in a patient, comprising administering to the patient a therapeutically effective amount of a cannabinoid CB 2 receptor agonist, wherein the agonist is O-1966. 2. The method as claimed in claim 1 , wherein the patient suffers from a disease selected from the group consisting of head trauma, stroke, cerebral bleeds, Alzheimer's and Parkinson's diseases and CNS inflammation in multiple sclerosis. 3. The method as claimed in claim 1 , wherein the agonist is administered in combination with a CB 1 receptor antagonist. 4. A pharmaceutical composition for cerebral ischemia/reperfusion injury or spinal cord injury in a patient in need thereof after the cerebral ischemia/reperfusion injury or spinal cord injury, comprising a therapeutically effective amount of a cannabinoid CB 2 receptor agonist, wherein the agonist is O-1966.
Assignees
Inventors
Classifications
- A61K31/045Primary
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates · CPC title
1,3-Diazoles · CPC title
carbocyclic · CPC title
having two or more such linkages · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9763894B2 cover?
- A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB 2 receptor but having substantially no efficacy at the CB 1 receptor at that amount.
- Who is the assignee on this patent?
- Martin Billy R, Damaj Mohamad Imad, Adler Martin W, and 7 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/045. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).